Corcept Therapeutics CORT Other Income (Expense)
Other Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Corcept Therapeutics's other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Corcept Therapeutics's other income (expense)?
- Corcept Therapeutics (CORT) reported other income (expense) of $4.89M in Q1 2026.
- How has Corcept Therapeutics's other income (expense) changed year-over-year?
- Corcept Therapeutics's other income (expense) decreased by 21.2% year-over-year, from $6.2M to $4.89M.
- What is the long-term trend for Corcept Therapeutics's other income (expense)?
- Over 4 years (2021 to 2025), Corcept Therapeutics's other income (expense) has grown at a 153.0% compound annual growth rate (CAGR), from $529K to $21.67M.
- What does other income (expense) mean?
- Income or expenses from sources outside of the company's main business activities.
- How do you interpret other income (expense)?
- Positive values indicate supplemental income sources, while negative values reflect debt servicing or investment losses.
- How does other income (expense) compare across companies?
- Highly variable based on capital structure and cash management strategies of the company.